Literature DB >> 22595374

Neurocognitive effects after brief pulse and ultrabrief pulse unilateral electroconvulsive therapy for major depression: a review.

Esmée Verwijk1, Hannie C Comijs, Rob M Kok, Harm-Pieter Spaans, Max L Stek, Erik J A Scherder.   

Abstract

BACKGROUND: Neurocognitive functioning is well known to be affected after ECT. However quantified data about the severity of the cognitive impairment after ultrabrief pulse and brief pulse ECT are limited, which makes it hard to judge its clinical relevance.
METHODS: To review all prospective studies using right unilateral (ultra) brief pulse index electroconvulsive therapy published up until February 2011 which used at least one instrument for cognitive assessment before and after ECT. The severity and persistence of neurocognitive side effects immediately (one to seven days post ECT), between one and six months and after six months post ECT were assessed by calculating effect sizes using Cohen's d.
RESULTS: Ten studies fulfilled the inclusion criteria and provided detailed information to compute effect sizes. The results indicate loss of autobiographical memory and impairment of verbal fluency, anterograde verbal and non-verbal memory immediately after brief pulse RUL ECT. To a lesser extent impairment of working memory and reduced speed of processing is found. Autobiographical memory is the only domain still being impaired between one and six months post ECT, but improved in this period. Verbal fluency normalized to baseline performance between one and six months post ECT whereas anterograde verbal and non-verbal memory normalized or even improved. Speed of processing improved within six months after ECT. Long-term data on these cognitive domains were not available. Based on two of the ten included studies the results suggest that ultrabrief pulse RUL ECT causes less decline in autobiographical and anterograde memory after ECT than brief pulse RUL ECT. LIMITATIONS: This review may be limited because of the small number of included studies and due to unreliable effect sizes. Furthermore, few data were available for non-memory domains and cognitive functioning after six months.
CONCLUSIONS: Loss of autobiographical memory is still present between one and six months after unilateral brief pulse ECT. Ultrabrief pulse RUL ECT shows less decline in autobiographical memory. Other neurocognitive impairments after brief pulse RUL ECT seem to be transient.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22595374     DOI: 10.1016/j.jad.2012.02.024

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  21 in total

1.  Short- and Long-term Cognitive Outcomes in Patients With Major Depression Treated With Electroconvulsive Therapy.

Authors:  Megha M Vasavada; Amber M Leaver; Stephanie Njau; Shantanu H Joshi; Linda Ercoli; Gerhard Hellemann; Katherine L Narr; Randall Espinoza
Journal:  J ECT       Date:  2017-12       Impact factor: 3.635

Review 2.  [Electroconvulsive therapy for the treatment of major depression].

Authors:  D Zilles; C Wolff-Menzler; J Wiltfang
Journal:  Nervenarzt       Date:  2015-05       Impact factor: 1.214

3.  Inflammatory cytokines derived from peripheral blood contribute to the modified electroconvulsive therapy-induced cognitive deficits in major depressive disorder.

Authors:  Haihua Tian; Guangxue Li; Guoan Xu; Jimeng Liu; Xiaohan Wan; Jiao Zhang; Shuguang Xie; Jia Cheng; Shugui Gao
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-02       Impact factor: 5.270

4.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

Review 5.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.

Authors:  Roumen V Milev; Peter Giacobbe; Sidney H Kennedy; Daniel M Blumberger; Zafiris J Daskalakis; Jonathan Downar; Mandana Modirrousta; Simon Patry; Fidel Vila-Rodriguez; Raymond W Lam; Glenda M MacQueen; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

6.  Individualized Low-Amplitude Seizure Therapy: Minimizing Current for Electroconvulsive Therapy and Magnetic Seizure Therapy.

Authors:  Angel V Peterchev; Andrew D Krystal; Moacyr A Rosa; Sarah H Lisanby
Journal:  Neuropsychopharmacology       Date:  2015-04-28       Impact factor: 7.853

7.  Similar clinical improvement of depression using 0.5-ms and 1-ms pulse widths in bilateral electroconvulsive therapy.

Authors:  Aida de Arriba-Arnau; Virginia Soria; Neus Salvat-Pujol; José M Menchón; Mikel Urretavizcaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-12-13       Impact factor: 5.270

Review 8.  Late-life depression: issues for the general practitioner.

Authors:  Axel Van Damme; Tom Declercq; Lieve Lemey; Hannelore Tandt; Mirko Petrovic
Journal:  Int J Gen Med       Date:  2018-03-29

Review 9.  The role of APOE-ɛ4 and beta amyloid in the differential rate of recovery from ECT: a review.

Authors:  T A Sutton; H R Sohrabi; S R Rainey-Smith; S M Bird; M Weinborn; R N Martins
Journal:  Transl Psychiatry       Date:  2015-03-31       Impact factor: 6.222

10.  Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.

Authors:  Sarah H Lisanby; Shawn M McClintock; William V McCall; Rebecca G Knapp; C Munro Cullum; Martina Mueller; Zhi-De Deng; Abeba A Teklehaimanot; Matthew V Rudorfer; Elisabeth Bernhardt; George Alexopoulos; Samuel H Bailine; Mimi C Briggs; Emma T Geduldig; Robert M Greenberg; Mustafa M Husain; Styliani Kaliora; Vassilios Latoussakis; Lauren S Liebman; Georgios Petrides; Joan Prudic; Peter B Rosenquist; Shirlene Sampson; Kristen G Tobias; Richard D Weiner; Robert C Young; Charles H Kellner
Journal:  Am J Geriatr Psychiatry       Date:  2021-05-17       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.